Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
UnitedHealthcare is the largest U.S. commercial insurer. Coverage of GLP-1 medications varies significantly by employer plan (UHC commercial) and government plan (UHC Medicare Advantage, UHC Medicaid).
Generally covered for T2D indication (Ozempic, Mounjaro, Trulicity). Typical copay $25–$100/month with PA.
Variable. Many UHC commercial plans cover Wegovy and Zepbound for weight indication with PA; some exclude weight management entirely as an employer-elected exclusion. Check your specific plan documents.
Many UHC plans cover Wegovy under the cardiovascular indication (March 2024 FDA approval) with PA criteria matching SELECT enrollment: BMI ≥27 + established CVD.
Coverage of Zepbound for OSA (December 2024 FDA approval) is being added to UHC formularies as of 2026; verify with your plan.
Typical PA criteria: BMI ≥30 or BMI ≥27 with weight-related comorbidity; documented attempt at lifestyle modification 3–6 months; some plans require step therapy.
Consider the CV or OSA indication if you qualify; appeal denials with detailed medical necessity documentation; consider cash-pay compounded GLP-1 as alternative.
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. Our editor's pick, NexLife, runs $145–$215/month flat-rate.